NCT05909995 - Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 29, 2023

Primary Completion Date

September 19, 2024

Study Completion Date

November 11, 2024

Conditions

MelanomaHepatocellular Carcinoma (HCC)Renal Cell Carcinoma (RCC)Microsatellite Instability - High (MSI-H)Mismatch Repair Deficient (dMMR)Colorectal Carcinoma (CRC)

Interventions

DRUG

INCB 99280 with Ipilimumab

Dose Escalation and expansion of INCB 99280 with Ipilimumab

Trial Locations (8)

37920

Alliance For Multispecialty Research Llc, Knoxville

48202

Henry Ford Health System, Detroit

90067

Valkyrie Clinical Trials, Los Angeles

92123

Sharp Memorial Hospital, San Diego

92868

UC Irvine Medical Center, Orange

M5G 2M9

Princess Margaret Cancer Center, Toronto

01692

Johese Clinical Research: Midstream, Centurion

00181

Mary Potter Oncology Centre, Pretoria